Results 71 to 80 of about 1,653 (153)

Assessing Second‐Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene‐Driven Stage IV Non‐Small Cell Lung Cancer, Following a First‐Line EGFR‐TKI Therapy

Cancer Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background Oncogene‐driven metastatic non‐small cell lung cancer (mNSCLC) is associated with poor survival outcomes, despite advancements in first‐line tyrosine kinase inhibitor (TKI) therapies. Aims This study aimed to characterise second‐line treatment strategies for epidermal growth factor receptor (EGFR)‐driven mNSCLC, and to evaluate ...
Meghana Maddula, Annelise Decaria, Bea Brown, John Simes, Michael Boyer, Venessa Chin   +5 more
wiley   +1 more source

Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection

, 2022
Oligoprogression is defined as limited metastatic clone resistant to on-going systemic treatment that grows in a background of stable or responding systemic disease.
Marzo, Marco Antonio, D'agostino, Giuseppe, Zucali, Paolo Andrea, Franzese, Ciro, Perrino, Matteo, Badalamenti, Marco, Marini, Beatrice, Scorsetti, Marta, Baldaccini, Davide, De Vincenzo, Fabio   +9 more
core   +1 more source

Progression and Metastasis of Lung Cancer: Clinical Features, Molecular Mechanisms, and Clinical Managements

MedComm, Volume 6, Issue 12, December 2025.
Lung cancer represents a significant global health threat. Despite progress in treatment, metastasis continues to present a major clinical challenge. This article reviews the metastases of lung cancer to the liver, bone, and brain, focusing on clinical symptoms, molecular mechanisms, and treatment strategies.
Yunkui Zhang, Meixi Chen, Xumeng Fang, Yu Han, Yingke Li   +4 more
wiley   +1 more source

Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide

, 2023
Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted ...
Fazio, Ivan, Ivan Fazio, Borsellino, Nicolò, La Vecchia, Maria, Galanti, Daniele, Nicolò Borsellino, Antonio Lo Casto, Daniele Galanti, Lo Casto, Antonio, Maria La Vecchia   +9 more
core   +1 more source

Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases

Clinical and Translational Radiation Oncology, 2020
Background: To investigate progression free survival (PFS), local control (LC) and overall survival (OS) outcomes for patients treated with spine hypofractionated stereotactic ablative radiotherapy (SABR) and to evaluate possible predictors of rapid ...
Charlotte Billiet, Ines Joye, Carole Mercier, Lieselotte Depuydt, Geert De Kerf, Peter Vermeulen, Steven Van Laere, Erik Van de Kelft, Paul Meijnders, Dirk Verellen, Piet Dirix   +10 more
doaj   +1 more source

Salvage Surgery Following Systemic Therapy in Initially Unresectable Non‐Small Cell Lung Cancer

Thoracic Cancer, Volume 16, Issue 24, December 2025.
Salvage pulmonary resection after systemic therapy for initially unresectable non‐small cell lung cancer achieved a high R0 rate with minimal morbidity and no perioperative mortality. Careful multidisciplinary selection facilitated a durable 5‐year survival rate of 75%.
Katsutoshi Seto, Yoshitsugu Horio, Katsuhiro Masago, Eiichi Sasaki, Hiroaki Kuroda, Yuta Matsubayashi, Hisanori Iwashimizu, Osamu Noritake, Keiyu Sato, Takuya Matsui, Soichiro Suzuki, Junichi Shimizu, Yutaka Fujiwara, Noriaki Sakakura   +13 more
wiley   +1 more source

Stereotactic body radiotherapy (SBRT) and concomitant systemic therapy in oligoprogressive breast cancer patients

, 2022
Breast cancer is a heterogenous disease with a deep tailoring level. Evidence is accumulating on the role of stereotactic body radiotherapy (SBRT) in the management of oligometastatic disease, however this is limited in breast cancer.
Rigo, Michele, Ricottone, Nicola, Jafari, Fatemeh, Alongi, Filippo, Ricchetti, Francesco, Giaj-Levra, Niccolò, Mazzola, Rosario, Nicosia, Luca, Maria Magrini, Stefano, Figlia, Vanessa, Girlando, Andrea, Cuccia, Francesco   +11 more
core   +1 more source

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy

International Journal of Breast Cancer, 2017
Purpose. Despite advances in endocrine therapy (ET), metastatic estrogen receptor positive breast cancer (BrCA) remains incurable. Though the mechanisms of resistance to ET have been studied extensively, the anatomic pattern of disease progression ...
Patrick Kelly, Zhe Ma, Said Baidas, Rebecca Moroose, Nikita Shah, Roi Dagan, Eleftherios Mamounas, Justin Rineer   +7 more
doaj   +1 more source

Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy

Cancer Communications, Volume 45, Issue 11, Page 1513-1546, November 2025.
Abstract Since its discovery, the cyclic GMP‐AMP synthase (cGAS)‐stimulator of the interferon gene (STING) signaling pathway has been considered a pivotal component of innate immunity and a promising target for cancer immunotherapy. Beyond its canonical role in pathogen defense, accumulating evidence has demonstrated that the cGAS‐STING pathway ...
Yuheng Yan, Ximin Tan, Bin Song, Ming Yi, Qian Chu, Kongming Wu   +5 more
wiley   +1 more source

Dataset related to article "Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection"

, 2022
This record contains raw data related to article "Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection" Abstract: Oligoprogression is ...
Perrino M, Badalamenti M, Marini B, Zucali PA, Marzo MA, D'Agostino G, De Vincenzo F, Franzese C, Scorsetti M, Baldaccini D   +9 more
core   +1 more source